Cigna's pharmacy benefits unit, Evernorth, is launching a new add-on to its pharmacy benefit management plans that will cap out-of-pocket costs for popular weight-loss drugs Wegovy and Zepbound at no more than $200 per month for patients. This initiative stems from a new agreement reached with drug manufacturers Eli Lilly and Novo Nordisk.
The program aims to significantly reduce prices for employers and their workers, making these high-cost medications more affordable and accessible. Harold Carter, Evernorth senior vice president of pharmacy relations, stated that clients currently covering weight loss drugs could see up to almost a 20% reduction in their costs with this updated arrangement.
In addition to cost caps, the new deal includes a simplified pre-authorization process for the drugs and ensures consistent pricing across retail pharmacies and Evernorth's home delivery service. This new weight-loss pricing program is scheduled to begin in the second half of the year, offering a competitive advantage in a rapidly growing market segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.